Axolotl Biologix Launches AxoBioFluid A™ an Ambient Temperature Amnion-Derived Allograft Fluid

PHOENIX, Sept. 13, 2017 /PRNewswire/ -- Axolotl Biologix, an innovator in regenerative medicine technologies that improve patient outcomes with less pain and lower costs, today announced that it will begin shipping its third amniotic allograft product, AxoBioFluid® A on October 1^st of this year.

AxoBioFluid® A is an ambient (room temperature) amniotic allograft fluid that is an alternative to the existing cryopreserved AxoBioFluid®. Both products are media conditioned by amniotic mesenchymal stromal cells (MSC) and amniotic epithelial cells (AEC), which contain associated growth factors that are released during cell culture. These growth factors, essential for fetal growth and development, have significant regenerative benefits when used as a treatment for various injuries and degenerative conditions. Both AxoBioFluid® products contain growth factors and cytokines that have been described in the peer-reviewed literature as anti-inflammatory, anti-fibrotic, vascular promoting, and proliferative. Additionally, these fluids  are immune-privileged in-utero; therefore, AxoBioFluid® is able to assist with soft tissue repair without the chance of immunorejection.

AxoBioFluid® A is available for order immediately and will start shipping on October 1^st. The product is available in four standard sizes 0.5ml, 1.0ml, 1.5ml, and 2.0ml, as well as custom sizes, which may be ordered.

"AxoBioFluid® A meets our customer demand to have an injectable product that can be stored at room temperature, ready for use, and has an extended shelf life. This is another example of our focus on providing significant improvements in patient outcomes, while delivering high value for clinicians," noted Bob Maguire, founder and CEO of Axolotl Biologix.

About Axolotl Biologix, Inc.

Axolotl Biologix, Inc., is expanding the human body's ability to regenerate by developing and manufacturing regenerative human cell and tissue medical technologies that are disrupting traditional, more invasive, painful, and expensive treatment protocols.  The Phoenix-based company is rapidly building a portfolio of unique, patented regenerative treatment products to improve patient outcomes with less pain and lower costs.  For more information, please visit the company's website at www.axobio.com.

Media Contact:

Bob Maguire
602-354-3081
[email protected]

SOURCE Axolotl Biologix

Related Links

http://www.axobio.com